Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001558370-24-008731
Filing Date
2024-05-29
Accepted
2024-05-29 16:15:43
Documents
47
Period of Report
2024-02-29

Document Format Files

Seq Description Document Type Size
1 10-K bzyr-20240229x10k.htm   iXBRL 10-K 1154775
2 EX-31.1 bzyr-20240229xex31d1.htm EX-31.1 12225
3 EX-31.2 bzyr-20240229xex31d2.htm EX-31.2 12005
4 EX-32.1 bzyr-20240229xex32d1.htm EX-32.1 7332
5 EX-32.2 bzyr-20240229xex32d2.htm EX-32.2 7377
  Complete submission text file 0001558370-24-008731.txt   3609310

Data Files

Seq Description Document Type Size
6 EX-101.SCH bzyr-20240229.xsd EX-101.SCH 32818
7 EX-101.CAL bzyr-20240229_cal.xml EX-101.CAL 19272
8 EX-101.DEF bzyr-20240229_def.xml EX-101.DEF 86517
9 EX-101.LAB bzyr-20240229_lab.xml EX-101.LAB 242024
10 EX-101.PRE bzyr-20240229_pre.xml EX-101.PRE 164294
51 EXTRACTED XBRL INSTANCE DOCUMENT bzyr-20240229x10k_htm.xml XML 320343
Mailing Address 9432 KATY FREEWAY HOUSTON TX 77055
Business Address 12000 RICHMOND AVE HOUSTON TX 77082 (713) 335-5697
BURZYNSKI RESEARCH INSTITUTE INC (Filer) CIK: 0000724445 (see all company filings)

EIN.: 760136810 | State of Incorp.: DE | Fiscal Year End: 0229
Type: 10-K | Act: 34 | File No.: 000-23425 | Film No.: 24998613
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)